However, although combination therapies have now been adopted, resistance against many existing antimalarials has been observed since the 1950s (Bishop, 1951; Hallinan, 1953; Sandosham et al. 1964) and remains a severe threat (Rieckmann & Cheng, 2002; Chinappi et al. 2010; Dondorp et al. 2010b; Newton et al. 2016; Parija, 2016; Menard & Dondorp, 2017; Zhou et al. 2017). This bleak view of the future of available anti-malarial chemotherapeutics makes it imperative to invest more efforts in identifying new potent chemotypes that will offer both efficacy and safety.